Cerebral dopamine neurotrophic factor (CDNF) is a recently discovered protein, which belongs to the evolutionarily conserved CDNF/MANF family of neurotrophic factors. The degeneration of dopamine neurons following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment is well characterized, and efficacy in this model is considered a standard criterion for development of parkinsonian therapies. MPTP is a neurotoxin, which produces parkinsonian symptoms in humans and in C57/Bl6 mice. To date, there are no reports about the effects of CDNF on dopamine neuron survival or function in the MPTP rodent model, a critical gap. Therefore, we studied whether CDNF has neuroprotective and neurorestorative properties for the nigrostriatal dopamine system after MPTP injections in C57/Bl6 mice. We found that bilateral striatal CDNF injections, given 20 h before MPTP, improved horizontal and vertical motor behavior. CDNF pretreatment increased tyrosine hydroxylase (TH) immunoreactivity in the striatum and in the substantia nigra pars reticulata (SNpr), as well as the number of TH-positive cells in substantia nigra pars compacta (SNpc). Posttreatment with CDNF, given 1 week after MPTP injections, increased horizontal and vertical motor behavior of mice, as well as dopamine fiber densities in the striatum and the number of TH-positive cells in SNpc. CDNF did not alter any of the analyzed dopaminergic biomarkers or locomotor behavior in MPTPuntreated animals. We conclude that striatal CDNF administration is both neuroprotective and neurorestorative for the TH-positive cells in the nigrostriatal dopamine system in the MPTP model, which supports the development of CDNF-based treatment for Parkinson's disease.
INTRODUCTION
. During the past decades, several neurotrophic factors have been studied in models of PD based on their postulated neuroprotective and neurorestorative proper-Parkinson's disease (PD) is a progressive neurodegenerative disease. Although many different neurons ties (5, 29) . The most studied and promising neurotrophic factor in animal models of PD thus far is glial cell line-degenerate at various levels of the neuraxis, the major symptoms that lead patients to seek treatment are caused derived neurotrophic factor (GDNF), which has been shown to be both neuroprotective and neuroregenerative by a loss of nigrostriatal dopamine neurons. At the moment, there is no clinical treatment either to slow against 6-hydroxydopamine (6-OHDA) in rats (19) and MPTP in mice (42). However, intraputamenal GDNF down and prevent the progression of the disease or to promote functional recovery by regenerating neurons treatment in human PD patients was not effective in a double-blind clinical trial (26), although two open label and neuronal connections.
Rodent models of PD have been well characterized. clinical studies, with small numbers of patients, showed clinical improvement (15, 38) . Thus, other proteins with Loss of dopaminergic circuitry can be induced in C57/ Bl6 mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-trophic activity on dopamine neurons need to be studied. One of these has been neurturin, a homologue of GDNF, dine (MPTP) through intraperitoneal (IP) injections and it has been shown to have both neuroprotective and saline (PBS) in a volume of 2 µl/side. A Hamilton syringe was lowered into striatum and the injection neurorestorative properties in several animal models of PD (9, 16) . Also, novel neurotrophic factors have been speed was 0.5 µl/min. The needle was left in place for 2 min after each injection. The dose, as well as produc-identified, like cerebral dopamine neurotrophic factor (CDNF) (31) and its homolog mesencephalic astrocyte-tion and purification of recombinant human CDNF protein, was chosen as previously described (31) . In both derived neurotrophic factor (MANF) (36) ; CDNF and MANF are secreted proteins that form a new evolution-neuroprotection and neurorestoration experiments mice were divided into the two treatment groups based on ary conserved protein family. MANF is protective on embryonic midbrain dopamine neurons in vitro (36) .
balancing their 24-h locomotor behavior before CDNF and PBS injections. Both CDNF and MANF are neuroprotective against intrastriatal 6-OHDA toxicity in rats and also promote functional recovery (31, 43, 44) . However, the effects of Behavioral Measurements CDNF or MANF in the MPTP mouse model of PD, one
The locomotor behavior of the mice was measured of the preclinical standards, have not been examined.
using an infrared activity monitor (Accuscan, Columbus, The aim of this study was to investigate whether OH). Each mouse was individually placed in a 42 × bilateral CDNF injections into striatum are protective 42 × 31-cm plexiglass chamber for a 24-h period, as preagainst MPTP and whether CDNF can promote funcviously described (11) . The apparatus contains 16 horitional recovery in adult mice after MPTP treatment. In zontal and 8 vertical infrared sensors placed 2.5 cm mice, MPTP treatment causes greater toxicity on dopaapart. Food and water were freely available throughout minergic nerve terminals in the striatum compared to the the experiment. Motor activity was calculated using the cell bodies in the substantia nigra pars compacta (SNpc) number of beams broken by the mice. (40) . Therefore, we administered CDNF bilaterally into the striata. We found that bilateral striatal CDNF injec-TH Immunostaining tions of 10 µg, given before MPTP injections, improved motor behavior and that when CDNF (10 µg) was After the behavioral experiments, mice were anesthetized and perfused with saline followed by 4% paraformaldehyde injected 1 week after MPTP there was also improved locomotor behavior. The effects of CDNF to produce (PFA) in phosphate buffer (PB). TH immunostaining was done on free-floating brain sections from striatum and behavioral improvement before or after MPTP were associated with increased striatal tyrosine hydroxylase substantia nigra using the ABC method as previously described (10,11). Briefly, sections were rinsed in 0.1 M (TH) immunoreactivity and substantia nigra dopamine (DA) cell numbers.
PB, pH 7.4, blocked with 4% bovine serum albumin (BSA) and 0.3% Triton X-100 in 0.1 M PB. Sections
MATERIALS AND METHODS
were then incubated in rabbit TH antibody (Millipore, Subjects and MPTP Injections #AB152, 1:500) overnight at 4°C. Sections were rinsed in 0.1 M PB and incubated in biotinylated horse anti-Adult male C57/Bl6 mice (Charles River Laborarabbit IgG (1:200; Vector Laboratories, Burlingame, tories, 10-12 weeks, 23-25 g) were used in the MPTP CA) for 1 h, followed by incubation for 1 h with avidinexperiments. Experimental procedures followed the NIH biotin-horseradish peroxidase complex. Staining was guidelines and were approved by the NIDA Animal developed with 2,3′-diaminobenzidine tetrahydrochlo-Care and Use Committee. MPTP (Sigma) was injected ride (0.5 mg/ml). Sections were then mounted on gelafour times at 2-h intervals using 15 and 20 mg/kg IP for tin/chrome alum-coated slides and coverslipped. pretreatment and posttreatment, respectively. The mouse
To determine the optical density the sections were strain, age, and weight were chosen to produce signifiscanned with Nikon Super Coolscan 9000. TH fiber dencant dopamine depletion and a clear behavioral phenosity from the dorsal striatum and SNpr was measured type (7, 22, 40) . The lower dose of MPTP in the from three brain sections and quantitated relative to the pretreatment experiment was used because of a significontrol group. For cell counts histological images were cant loss of mice with higher dose, probably due to acquired using an Infinity 3 camera, NIKON 80i microweaker physical condition after the survival surgery on scope, and QCapture Pro 5.0 software. TH-positive cells the previous day.
were averaged from three sections (AP: −3.16 mm, Surgical Procedures −3.40 mm, −3.64 mm to bregma) as described previously (11) . Image analysis was carried out with NIS Mice were anesthetized with chloral hydrate (400 mg/kg, IP) and placed in a stereotaxic apparatus. Mice elements software (Nikon). The quantitation of TH-positive cells was carried out using stereology and all mea-were injected bilaterally into striatum (AP 0.5, ML 1.7, DV −3.5) with 10 µg CDNF or phosphate-buffered surements were done by personnel blinded as to treatment. TH pixel density was obtained by subtracting g for 15 min. Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) were the background density. measured by HPLC with electrochemical detection (25) .
NeuN Immunofluorescent Staining
The analytical column was a Symmetry C18 3.5 µm, Sections were rinsed three times with PB and incu-4.6 × 150.0 mm (Waters, Milford, MA), and the mobile bated for 1 h with blocking solution (4% BSA in 0.3% phase consisted of 0.01 M sodium dihydrogen phos-Triton X-100 in PB). Sections were then incubated overphate, 0.01 M citric acid, 2 mM sodium ethylenedinight with mouse anti-NeuN antibody (neuronal nuclei, aminetetraacetic acid (EDTA), 1 mM sodium octyl 1:200, Chemicon) and rabbit anti-TH antibody and sulfate, 10% methanol, and the pH was 3.5. A flow rate rinsed three times in PB. The primary antibody was visof 0.9 ml/min was used and temperature was set to ualized using the AlexaFluor 488 goat anti-mouse or 25°C. The system consisted of an ESA automated injec-AlexaFluor 568 goat anti-rabbit secondary antibody tion system, an ESA 582 pump, and a Coulochem III (Invitrogen). Brain sections were examined with a detector (ESA, Chelmsford, MA). An EZChrom Elite TM Nikon eclipse 80i microscope with a Q-imaging camera. chromatography data analysis system (ESA Biosciences, Fluorescence intensity of NeuN-positive nuclei was Inc.) was used for data collection and analysis. Levels quantified in the SNpc from three sections of each brain of DA, DOPAC, and HVA were calculated as nmol/g of area and averaged using NIS Elements software. The tissue weight. images were adjusted equivalently for brightness and contrast for visualization.
Effects of CDNF in MPTP-Naive Animals
Two additional experiments were carried out to ana-Western Blotting lyze whether CDNF affects the dopaminergic system in Samples were sonicated for 10 s in 100 µl of RIPA MPTP-untreated naive animals. In the first experiment lysis buffer with 1× protease inhibitor cocktail (Sigmamice were balanced into two groups based on their basal Aldrich, P8340) and centrifuged at 10,000 × g for 5 min.
locomotor behavior and injected bilaterally into striatum The supernatants were collected for TH Western blots either with PBS or CDNF 10 µg, and an additional eight and protein concentrations were measured using the DC normal mice were used as controls. After 2 weeks 24-h assay (Bio-Rad). The pellet was eluted with 50 µl 1% locomotor behavior was monitored and mice were sodium dodecyl sulfate (SDS) and used for dopamine decapitated, their brains removed, rapidly frozen in transporter (DAT) Western blot and protein concentra-−50°C isopentane, and stored at −80°C. Bilateral tissue tion measurements. Lysates were diluted with punches of the striatum and SN were taken from 1-mm NuPAGE lithium dodecyl sulfate (LDS) sample buffer coronal sections cut in a cryostat at −20°C. The other and 2-mercaptoethanol and heated at 70°C for 10 min. side was used for Western blot experiments and the For TH analysis 20 µg and for DAT analysis 10 µg of other side for HPLC analysis. protein was loaded into 4-12% Bris-Tris gel (NuPAGE;,
In another set of experiments, 31 Wistar rats (250-Invitrogen) and the electrophoresis was carried out in 1× 280 g) were injected with vehicle, GDNF 10 µg, or MOPS [3-(N-morpholino)propanesulfonic acid] buffer CDNF 10 µg unilaterally into the striatum. These exper-(Invitrogen). The proteins in the gel were transferred iments were approved by the Committee for Animal onto nitrocellulose membranes using NuPAGE transfer Experiments of the University of Helsinki and the Chief buffer (Invitrogen). The Western blot procedures were veterinarian of the County Administrative Board. Two carried out according to the Odyssey protocol. Actin weeks later animals were given d-amphetamine (2.5 mg, mouse antibody (1:1000 MAB1501, Millipore) was used SC) and, subsequently, motor behavior was measured as an endogenous control. TH was detected using an for 2 h. Afterwards animals were perfused, and TH anti-TH rabbit antibody (1:1000, AB152, Millipore) and immunostaining and cell counts in pars compacta and DAT was detected using rat anti-DAT antibody (1:1000, TH optical density in pars reticulata were carried out as MAB369, Millipore). Infrared-labeled secondary antidescribed above. bodies of goat anti-mouse, anti-rabbit, and anti-rat were used for actin, TH, and DAT, respectively. After immu-Statistical Analysis nostaining, the membranes were scanned by a Li-Cor Student's t-test and one-and two-way ANOVA were Odyssey Scanner and the bands were analyzed using used for statistical analysis. In the two-way ANOVA the ImageJ software.
within-subjects factor used was time and the between-High Performance Liquid Chromatography subjects factor was CDNF dose. Bonferroni test was (HPLC) Analysis used for post hoc analysis. Data are presented as mean ± SEM and a value of p < 0.05 was considered statisti-The tissues obtained from each animal were homogenized in 0.1 M perchloric acid and centrifuged at 13,000 × cally significant.
RESULTS

CDNF Protects TH-Positive Neurites and Cell Bodies Against MPTP-Induced Toxicity
Mice were balanced into treatment groups according to their 24-h behavior (Fig. 1A, B , blue columns). CDNF or PBS injections were given into striatum 20 h prior to MPTP (15 mg/kg, IP ×4, every 2 h). Locomotor behavior over 24 h was measured 2 weeks later. CDNFtreated mice manifested a significantly greater distance traveled ( Fig. 1A) . Statistical analysis showed significant effects of Time [F(1, 13) = 10.5, p < 0.01] and CDNF dose [F(1, 13) = 5.1, p < 0.05], but not Time × CDNF dose interaction [F(1, 13) = 3.3, two-way ANOVA]. The Bonferroni post hoc test showed a significant difference between PBS and CDNF injected mice on week 2 (p < 0.05). To further analyze the temporal difference between these two groups, a two-way ANOVA was carried out at 2-h intervals. The major difference between the groups was in the dark cycle, hours 12-24, when the mice were more active. Pretreatment with CDNF significantly increased total distance traveled [F(1, 13) = 7.3, p < 0.05] (Fig. 1A, right panel) . CDNF-treated mice also showed a significantly greater vertical activity ( the groups was during the dark cycle [F(1, 13) = 11.7, p 0.40, one-way ANOVA) ( Fig. 3B ), or DAT levels in the striatum (p = 0.64, one-way ANOVA) ( Fig. 3C, E) . There < 0.01] (Fig. 1B, right panel) .
Immunohistochemical analysis showed that bilateral were no differences in DA, DOPAC, and HVA concentrations in the striatum or SN between CDNF-and PBS-striatal CDNF injections protected TH-positive nerve fibers against MPTP treatment in the striatum (p < 0.01, treated mice (p > 0.05, Student's t-test) ( Table 1) . However, DOPAC/DA ratio, an indicator of dopamine metabo-Student's t-test) (Fig. 1C) . In PBS-treated mice 27% of TH-positive neurites were spared and in CDNF-treated lism, and DOPAC + HVA/DA ratio, an indicator of dopamine turnover, were significantly higher in the stria-mice 62%, compared to MPTP-naive normal mice. CDNF injections also protected neurites in the SNpr tum of CDNF-treated mice (p < 0.01 and p < 0.05, respectively, Student's t-test). (p < 0.05, t-test) (Fig. 1D) . In SNpr TH-positive neurites were 61% in PBS-treated mice and 85% in CDNF-Thirty-one rats were injected with vehicle, GDNF 10 µg, or CDNF 10 µg unilaterally into the striatum. Two treated mice compared to MPTP-naive normal mice. Intrastriatal CDNF treatment also significantly rescued weeks later animals were given d-amphetamine (2.5 mg/ kg, SC) and, subsequently, motor behavior was mea-TH-positive cells in the SNpc in the MPTP-treated mice (p < 0.05, t-test) (Fig. 1E ). The numbers of TH-positive sured for 2 h. Afterwards animals were perfused, and TH immunostaining and cell counts in pars compacta cells were 44% in PBS-treated mice and 85% in CDNFtreated mice compared to nonlesioned naive mice. and TH optical density in pars reticulata were carried out as described above. Locomotor activity, induced by Selectivity of CDNF-Mediated Neuroprotection in SNpc d-amphetamine, did not differ between vehicle, CDNF, and GDNF treatment groups [vehicle: 100 ± 14, CDNF: A question that arises from the results is whether the CDNF-induced neuroprotective effect is selective to 113 ± 24, GDNF: 123 ± 26; values are related to vehicle, F(2, 28) = 0.26, p = 0.74, one-way ANOVA] (Fig. dopamine neurons or is it secondary to the prevention of cell loses in SNpc. To study this, a set of brain sec-3F). The number of TH-positive cells was similar in all treatment groups [vehicle: 89 ± 5, CDNF 95 ± 8, tions from experiment one was double stained with NeuN (a marker for neurons, green) and TH (red, Fig. GDNF: 98 ± 8; values are related to the number of THpositive cells in the nontreated hemisphere, F(2, 26) = 2). Since NeuN-positive cells do not correlate well with TH-positive cells in SNpc (6, 14) , NeuN can be used as 0.43, p = 0.65, one-way ANOVA] (Fig. 3G) . In addition, TH optical density in the SNpr was similar in all a marker for other neuronal populations in SNpc. No difference in NeuN fluorescence intensity in SNpc was treatment groups [vehicle: 100 ± 10, CDNF: 91 ± 7, GDNF: 109 ± 8; values are normalized to the TH optical found between PBS + MPTP-treated mice and CDNF + MPTP-treated mice (p = 0.21, Student's t-test) while a density in the control group, F(2, 25) = 0.93, p = 0.41, one-way ANOVA] (Fig. 3H ). significant increase in TH immunoreactivity was found in mice pretreated with CDNF. These data suggest that CDNF Promotes Recovery After MPTP Injections CDNF-mediated protection is selective for dopamine neurons in substantia nigra.
Twenty-eight mice were injected with four doses of MPTP at 2-h intervals. Animals were equally separated CDNF Does Not Alter Behavior or TH into two groups according to their locomotor activity 1
Immunoreactivity in MPTP Naive Animals
week after MPTP injections and were treated with either CDNF or PBS into the striatum. Posttreatment with Another question that arises from the previous results is does CDNF increase TH immunoreactivity in MPTP-CDNF, compared to PBS, significantly improved total distance traveled (p < 0.05, t-test) (Fig. 4A ) and vertical naive mice that might cause a neuroprotective effect simply by raising TH protein levels? Two experiments were activity (p < 0.05, t-test) (Fig. 4B ) over 24 h at 1 week after injection. The analysis at 2-h intervals with two-carried out to analyze whether CDNF affects the dopaminergic system in MPTP-untreated naive animals. Sixteen way ANOVA further indicated that there was a significant difference in distance traveled [F(1, 26) = 5.7, p < mice were balanced into two groups based on their basal locomotor behavior and injected bilaterally into striatum 0.05] (Fig. 4A ) and vertical activity [F(1, 26) = 7.1, p < 0.05] (Fig. 4B) after CDNF treatment during the dark either with PBS or 10 µg of CDNF, and an additional eight normal mice were used as controls. Two weeks later period. Bilateral striatal CDNF 10 µg injections incremented TH-positive nerve fiber immunoreactivity after locomotor behavior, striatal TH and DAT levels, and DA, DOPAC, and HVA concentrations were analyzed (Fig. 3) .
MPTP-induced toxicity in the striatum (p < 0.05, t-test) (Fig. 4C) . In striatum TH-positive neurites were 15% in No difference in horizontal or vertical 24-h locomotor activity was found between PBS and CDNF groups (data PBS-treated mice and 31% in CDNF-treated mice compared to MPTP-naive mice. CDNF did not alter TH opti-not shown). CDNF did not alter TH levels in the striatum (p = 0.25, one-way ANOVA) (Fig. 3A, D) , in SN (p = cal density in the SNpr (Fig. 4D ). However, CDNF treatment significantly increased the number of TH-pos-on adult dopamine neurons in MPTP-lesioned mice. We found that CDNF (10 µg) injections, given bilaterally itive cells in the SNpc compared to PBS treatment (p < 0.05, t-test) (Fig. 4E) . In SNpc TH-positive cells were into the striatum before MPTP injections, improved locomotor behavior and increased TH immunoreactivity 51% in PBS-treated mice and 65% in CDNF-treated mice as relation to MPTP-naive normal mice.
in the striatum and SNpr, and also protected TH-positive cells in the SNpc significantly. Furthermore, when administered 1 week after MPTP, CDNF improved loco-DISCUSSION motor behavior and increased TH immunoreactivity in the striatum and the number of TH-positive cells in The present results show that CDNF can protect against MPTP toxicity and restore motor function in SNpc. These results suggest that CDNF treatment not only protects the cell bodies of midbrain dopamine mice when given before or after MPTP. Here we provide both histochemical and behavioral evidence indi-neurons from degeneration but also restores dopaminergic circuitry. cating that CDNF exerts positive neurotrophic effects We used MPTP in C57/Bl6 mice to elicit disruption many neuronal elements are still present, albeit with a loss of the dopamine phenotype (28) . Indeed, the con-of midbrain dopamine circuits. MPTP is a neurotoxin that affects nigrostriatal dopamine neurons in humans, cept of neurorestoration therapy in PD is to restore the function of neurons that are still viable. The present in nonhuman primates, and in mice, and produces motor symptoms resembling PD (22, 39) . In humans and non-experiments do not distinguish between whether CDNF facilitates restoration of the dopamine phenotype or human primates MPTP irreversibly destroys the midbrain dopamine neurons. C57/Bl6 mice are susceptible regeneration of dopamine neurons, which could occur through neural progenitor cells (20). To answer this to MPTP and dopamine terminals are destroyed transiently; there is some spontaneous regeneration from the question would require an extensive time course followup and prelabeling of dopamine neurons. surviving cells at many weeks to months after lesioning. Hence, it is important to examine toxicity within a 2-4-
The finding that CDNF-induced neuroprotection was stronger than the effects found in the neurorestorative week window (12) . There is still ongoing debate whether MPTP treatment in mice does cause death of experiments is also in line with previous findings with CDNF (31) , MANF (44) , and GDNF (42). It is likely dopamine neurons or loss of dopamine phenotype. In two studies it has been indicated that there is loss of that early treatment with these trophic factors may more effectively reduce DA fiber degeneration. dopamine cells in SNpc followed up to 2 or 4 weeks after MPTP administration, respectively (3, 21) . How-Although GDNF has been shown to be a potent survival factor for embryonic dopaminergic neurons in ever, in other studies where mice have been followed up to 5 and 6 months it has been reported that there is par-vitro, there is some controversy about whether GDNF provides neuroprotection in addition to its well-estab-tial spontaneous recovery (35, 37) . Our finding that CDNF can promote recovery is in line with the latter lished neurorestoration properties in mouse MPTP models. Tomac and coworkers, using a similar experimental studies and suggests that some of the MPTP-induced toxic effects can be reversed. If dopamine cells would design as in this study, found that exogenous GDNF is protective against MPTP and promotes recovery (42). In be totally degenerated, CDNF and any other neurotrophic factor may not show restorative properties. It a study by Cheng and coworkers MPTP (35 mg/kg, SC) was injected once daily for 7 days and GDNF was should be kept in mind that in advanced human PD injected unilaterally into striatum either before, during, genes, whereas invertebrates contain only a single homolog (30) . In Drosophila it has been shown that or after MPTP treatment (8) . Although this study failed to show a correlation between behavior and the extent deletion of MANF results in degeneration of dopamine axons and a significant decrease in dopamine concentra-of the lesion, GDNF pretreatment and posttreatment increased dopamine concentrations in the striatum. A tion (33) . In the adult mouse brain, both CDNF and MANF proteins are detected mostly in the neurons in study by Kojima and coworkers found that adenovirus mediated GDNF overexpression increased dopamine the striatum, substantia nigra, cortex, hippocampus, and cerebellum, and MANF has also been localized to some levels in striatum when the virus was given 1 week after MPTP (2 doses of 40 mg/kg, SC, on consecutive days) dopamine neurons (30, 31) . These data suggest that CDNF is present endogenously in adult brain. In this exposure (23) . In contrast, a study by Eberhardt and coworkers, where adenovirus GDNF was injected into study, we found that exogenously applied CDNF did not upregulate TH and DAT or alter dopamine concentra-striatum and 1 week later MPTP (30 mg/kg, IP) was injected daily for 5 consecutive days, it was found that tions in MPTP-naive animals. We found that DOPAC/ DA and DOPAC + HVA/DA ratios were increased after GDNF overexpression alone did not produce neuroprotection of dopamine neurons (13) . Also, another study CDNF treatment, suggesting that dopamine metabolism and turnover is increased. However, the effect of by the same group, where the same MPTP treatment protocol and a conditional rearranged during transfec-increased dopamine turnover was not associated with increased horizontal or vertical locomotor activity, and tion (RET)-deficient mouse model was used, indicated that endogenous GDNF-RET signaling does not provide therefore the physiological role of CDNF in dopamine neurons in nonlesioned animals is not clear at present. protection against MPTP-induced cell loss (24). Taken together these studies suggest that GDNF's most promi-Furthermore, our results in nonlesioned animals suggest that the neuroprotective effect observed is not due to nent effect in the MPTP-lesioned mouse midbrain is to facilitate regrowth of the dopaminergic axon terminals. simply increased TH or DAT levels.
In rats it has been reported that NeuN-positive cells Consistent with clinical findings (26) it is likely that GDNF's beneficial effect may be limited to selective do not correlate well with TH-positive cells in SNpc (6) and a study with cynomolgus monkeys showed no corre-aspects of PD. In this study, we report that CDNF protects the cell bodies of dopamine neurons when given lation between histological markers of cellular death and NeuN in SNpc after MPTP administration (14) . As we before or after lesioning, revealing beneficial properties of this novel neurotrophic factor that may provide addi-did not find any differences in the levels of NeuN-positive cells in SNpc, our results suggest that the neuropro-tional beneficial effects in PD patients.
Structural analysis of CDNF and MANF indicates tective effect of CDNF is selective for dopamine neurons. However, this conclusion should be considered that they are two-domain proteins (34) . The CXXC disulphide bridge of the carboxy-terminal domain with caution since there are no published data about the effects of MPTP on the number of NeuN-positive cells resembles the active site of oxidoreductases and isomerases, which may be involved in endoplasmic reticulum in SNpc in mice.
In conclusion, the present study is the first to report (ER) stress function; the amino-terminal domain is homologous to saposins, which are proteins known to the positive neuroprotective and neurorestorative effects of intrastriatal CDNF administration in the nigrostriatal bind lipids (34) . Recent studies indicate that the C-terminal part of MANF is crucial for protective effects against dopamine system against MPTP. CDNF had neuroprotective effects on dopamine cell bodies when MPTP was apoptotic cell death and it resembles SAP domain of Ku70 that can bind to and block the proapoptotic mole-given either before or after striatal CDNF injections. Furthermore, CDNF neither altered TH and DAT cule Bax (18) . MANF and CDNF are expressed in neurons and in nonneuronal tissue (30, 31) , and the expression levels nor dopamine and its metabolite concentrations in the nigrostriatal dopamine system in expression of MANF is increased by tunicamycin, ischemia, and status epilepticus (4, 27, 30, 32, 41) . MANF pro-MPTP-naive animals. These results further support the development of CDNF-based treatment strategies to stop tects cells from tunicamycin, an inhibitor of N-linked glycosylation and an agent known to produce ER stress progression or to promote recovery in PD. (4) . MANF also protects neurons against cerebral ische-ACKNOWLEDGMENTS: This research was supported by the IRP of NIDA, NIH, DHHS. We would like to thank Carl Lup-mia in vivo (1, 2) . The mechanisms underlying these ica, Alex Hoffman, and Christopher Richie for their help with functions may also be involved in the neuroprotective the study. The authors declare no conflicts of interest. and restorative effects of CDNF against MPTP.
The role of CDNF in the normal development or REFERENCES maintenance of dopamine neurons is not well character-
